Lexicon Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Vocabulary Pharmaceuticals, Inc. (previously Lexicon Genetic) a biopharmaceutical organization, centers around the disclosure and improvement of drug items for the treatment of human infection, including immunology, digestion, cardiology, and ophthalmology. The organization's medication competitors incorporate LX1031, which has finished Phase II clinical preliminaries for the treatment of peevish entrail condition and other gastrointestinal problems; LX4211 that has finished Phase II clinical preliminaries to treat type 2 diabetes; LX2931, which is in Phase II clinical preliminaries for the treatment of rheumatoid joint pain and other immune system illnesses; and LX1032 that has finished Phase II clinical preliminaries to treat the side effects related with carcinoid disorder. It likewise has a preclinical improvement drug competitor, LX7101, for the treatment of glaucoma. The organization has drug disclosure coalitions with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It likewise has drug improvement funding cooperation with Symphony Icon; joint effort concurrence with Taconic Farms, Inc.; and a partnership with Nuevolution A/S, which gives admittance to Nuevolution's Chemetics stage science innovation.
Lexicon Pharmaceuticals has raised $320M across 4 funding rounds on record, the most recent an undisclosed round of $55.0M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lexicon Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: May 2026.
Lexicon Pharmaceuticals Funding Rounds
Lexicon Pharmaceuticals raised $150M in a Post-IPO Debt announced in Mar 2022.
4 months later, a Post-IPO Equity of $42.9M was announced in Jul 2022.
11 months later, an undisclosed round of $72.2M was announced in Jun 2023.
2.9 years later, an undisclosed round of $55.0M was announced in May 2026.
Lexicon Pharmaceuticals Founders and Leadership Team
Contact details for the Lexicon Pharmaceuticals team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Lexicon Pharmaceuticals Funding Compared to Other Biotechnology Startups
Lexicon Pharmaceuticals' latest round of $55.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lexicon Pharmaceuticals in Biotechnology and The Woodlands
Companies Similar to Lexicon Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Lexicon Pharmaceuticals Funding FAQs
What does Lexicon Pharmaceuticals do?
Vocabulary Pharmaceuticals, Inc. (previously Lexicon Genetic) a biopharmaceutical organization, centers around the disclosure and improvement of drug items for the treatment of human infection, including immunology, digestion, cardiology, and ophthalmology. The organization's medication competitors incorporate LX1031, which has finished Phase II clinical preliminaries for the treatment of peevish entrail condition and other gastrointestinal problems; LX4211 that has finished Phase II clinical preliminaries to treat type 2 diabetes; LX2931, which is in Phase II clinical preliminaries for the treatment of rheumatoid joint pain and other immune system illnesses; and LX1032 that has finished Phase II clinical preliminaries to treat the side effects related with carcinoid disorder. It likewise has a preclinical improvement drug competitor, LX7101, for the treatment of glaucoma. The organization has drug disclosure coalitions with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It likewise has drug improvement funding cooperation with Symphony Icon; joint effort concurrence with Taconic Farms, Inc.; and a partnership with Nuevolution A/S, which gives admittance to Nuevolution's Chemetics stage science innovation.
How much funding has Lexicon Pharmaceuticals raised?
Lexicon Pharmaceuticals has raised $320M across 4 rounds on record. The most recent is an undisclosed round of $55.0M announced in May 2026.
When did Lexicon Pharmaceuticals last raise funding?
Lexicon Pharmaceuticals' most recent funding round on record is an undisclosed round of $55.0M, announced in May 2026.
Who founded Lexicon Pharmaceuticals?
FundedIQ lists Mike Exton (Founder) at Lexicon Pharmaceuticals.
Who is the CEO of Lexicon Pharmaceuticals?
Lonnel Coats is listed as CEO at Lexicon Pharmaceuticals.
Where is Lexicon Pharmaceuticals headquartered?
Lexicon Pharmaceuticals is based in The Woodlands, Texas, United States.
How many employees does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals is in the 251-500 employee band.
How does Lexicon Pharmaceuticals' funding compare to other Biotechnology startups?
Lexicon Pharmaceuticals' latest round of $55.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Lexicon Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lexicon Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.